Epigenetic mechanisms of macrophage activation in type 2 diabetes

Immunobiology

Volumn 222, Issue 10, 2017, Pages 937-943

  Ahmed, Mohamed ^a   de Winther, Menno P J ^a,b   Van den Bossche, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Epigenetics; Inflammation; Macrophage activation; Obesity; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT6 PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; CELL HYPOXIA; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVATION; EPIGENETICS; HISTONE ACETYLATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IN VITRO STUDY; INSULIN RESISTANCE; MACROPHAGE ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; EPIGENESIS, GENETIC; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGES; MOLECULAR TARGETED THERAPY;

EID: 84995554866     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2016.08.011     Document Type: Review

References (82)

1. Ahmed, N., Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 67 (2005), 3–21, 10.1016/j.diabres.2004.09.004.
2. Arany, Z., et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 12969–12973.
3. Arguelles, A.O., Meruvu, S., Bowman, J.D., Choudhury, M., Are epigenetic drugs for diabetes and obesity at our door step?. Drug Discovery Today, 2015, 10.1016/j.drudis.2015.12.001.
4. Babu, M., et al. Differential promoter methylation of macrophage genes is associated with impaired vascular growth in ischemic muscles of hyperlipidemic and type 2 diabetic mice: genome-Wide promoter methylation study. Circ. Res. 117 (2015), 289–299, 10.1161/CIRCRESAHA.115.306424.
5. Barrett, E., Brothers, S., Wahlestedt, C., Beurel, E., I-BET151 selectively regulates IL-6 production. Biochim. Biophys. Acta 1842 (2014), 1549–1555, 10.1016/j.bbadis.2014.05.013.
6. Belkina, A.C., Nikolajczyk, B.S., Denis, G.V., BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 190 (2013), 3670–3678, 10.4049/jimmunol.1202838.
7. Brasacchio, D., et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58 (2009), 1229–1236, 10.2337/db08-1666.
8. Brem, H., Tomic-Canic, M., Cellular and molecular basis of wound healing in diabetes. J. Clin. Invest. 117 (2007), 1219–1222, 10.1172/JCI32169.
9. Cedar, H., Bergman, Y., Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10 (2009), 295–304, 10.1038/nrg2540.
10. Christensen, D.P., et al. Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and beta-cell protection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 1055–1059, 10.1073/pnas.1320850111.
11. De Santa, F., et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 28 (2009), 3341–3352, 10.1038/emboj.2009.271.
12. Di Marco, E., Gray, S.P., Jandeleit-Dahm, K., Diabetes alters activation and repression of pro- and anti-inflammatory signaling pathways in the vasculature. Front. Endocrinol., 4, 2013, 68, 10.3389/fendo.2013.00068.
13. Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11 (2011), 98–107, 10.1038/nri2925.
14. Ea, C.K., Baltimore, D., Regulation of NF-kappaB activity through lysine monomethylation of p65. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 18972–18977, 10.1073/pnas.0910439106.
15. Eguchi, K., et al. Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab. 15 (2012), 518–533, 10.1016/j.cmet.2012.01.023.
16. Fang, T.C., et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J. Exp. Med. 209 (2012), 661–669, 10.1084/jem.20112343.
17. Filippakopoulos, P., Knapp, S., Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discovery 13 (2014), 337–356, 10.1038/nrd4286.
18. Fu, W., et al. Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and beta cells. eLife, 3, 2014, e04631, 10.7554/eLife.04631.
19. Fujisaka, S., et al. Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in an HIF-1alpha-dependent and HIF-1alpha-independent manner in obese mice. Diabetologia 56 (2013), 1403–1412, 10.1007/s00125-013-2885-1.
20. Gallagher, K.A., et al. Epigenetic changes in bone marrow progenitor cells influence the inflammatory phenotype and alter wound healing in type 2 diabetes. Diabetes 64 (2015), 1420–1430, 10.2337/db14-0872.
21. Galvan-Pena, S., O'Neill, L.A., Metabolic reprograming in macrophage polarization. Front. Immunol., 5, 2014, 420, 10.3389/fimmu.2014.00420.
22. Gosselin, D., Glass, C.K., Epigenomics of macrophages. Immunol. Rev. 262 (2014), 96–112, 10.1111/imr.12213.
23. Gregor, M.F., Hotamisligil, G.S., Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29 (2011), 415–445, 10.1146/annurev-immunol-031210-101322.
24. Gross, T.J., et al. Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses. J. Immunol. 192 (2014), 2326–2338, 10.4049/jimmunol.1301758.
25. Halili, M.A., et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the toll-like receptor 4 agonist LPS. J. Leukoc. Biol. 87 (2010), 1103–1114, 10.1189/jlb.0509363.
26. Hanson, M.A., Godfrey, K.M., Genetics Epigenetic mechanisms underlying type 2 diabetes mellitus. Nat. Rev. Endocrinol. 11 (2015), 261–262, 10.1038/nrendo.2015.31.
27. Hattori, Y., Hattori, K., Hayashi, T., Pleiotropic benefits of metformin: macrophage targeting its anti-inflammatory mechanisms. Diabetes 64 (2015), 1907–1909, 10.2337/db15-0090.
28. Hoeksema, M.A., et al. Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Mol. Med. 6 (2014), 1124–1132, 10.15252/emmm.201404170.
29. Ishii, M., et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 114 (2009), 3244–3254, 10.1182/blood-2009-04-217620.
30. Ivashkiv, L.B., Epigenetic regulation of macrophage polarization and function. Trends Immunol. 34 (2013), 216–223, 10.1016/j.it.2012.11.001.
31. Jin, X., et al. Advanced glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-kappaB pathway. BioMed Res. Int., 2015(732450), 2015, 10.1155/2015/732450.
32. Kanda, H., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116 (2006), 1494–1505, 10.1172/JCI26498.
33. Kanety, H., Feinstein, R., Papa, M.Z., Hemi, R., Karasik, A., Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1): possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J. Biol. Chem. 270 (1995), 23780–23784.
34. Ke, Q., Costa, M., Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70 (2006), 1469–1480, 10.1124/mol.106.027029.
35. Kimball, A., Joshi, A., Henke, P.K., Kunkel, S., Gallagher, K., Altered histone methylation at the IL-1 B promoter in diabetic macrophages enhances inflammation and impairs wound healing. J. Vasc. Surg., 61, 2015, 176s.
36. Kittan, N.A., et al. Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One, 8, 2013, e78045, 10.1371/journal.pone.0078045.
37. Kraakman, M.J., Murphy, A.J., Jandeleit-Dahm, K., Kammoun, H.L., Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function?. Front. Immunol., 5, 2014, 470, 10.3389/fimmu.2014.00470.
38. Kruidenier, L., et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488 (2012), 404–408, 10.1038/nature11262.
39. Lawrence, T., Natoli, G., Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 11 (2011), 750–761, 10.1038/nri3088.
40. Lee, J., Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes. Arch. Pharmacal Res. 36 (2013), 208–222, 10.1007/s12272-013-0023-8.
41. Lehuen, A., A double-edged sword against type 1 diabetes. N. Engl. J. Med. 372 (2015), 778–780, 10.1056/NEJMcibr1414708.
42. Li, Y., et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J. Biol. Chem. 283 (2008), 26771–26781, 10.1074/jbc.M802800200.
43. Li, M.F., et al. High glucose increases the expression of inflammatory cytokine genes in macrophages through H3K9 methyltransferase mechanism. J. Interferon Cytokine Res. 36 (2016), 48–61, 10.1089/jir.2014.0172.
44. Lim, E.L., et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54 (2011), 2506–2514, 10.1007/s00125-011-2204-7.
45. Liu, K., Zhou, R., Wang, B., Mi, M.T., Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 99 (2014), 1510–1519, 10.3945/ajcn.113.082024.
46. Lumeng, C.N., Bodzin, J.L., Saltiel, A.R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117 (2007), 175–184, 10.1172/JCI29881.
47. Lundh, M., Galbo, T., Poulsen, S.S., Mandrup-Poulsen, T., Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obesity Metab. 17 (2015), 703–707, 10.1111/dom.12470.
48. Maedler, K., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110 (2002), 851–860, 10.1172/JCI15318.
49. Mantovani, A., Locati, M., Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler. Thromb. Vasc. Biol. 33 (2013), 1478–1483, 10.1161/ATVBAHA.113.300168.
50. Matias, M.A., Saunus, J.M., Ivanovski, S., Walsh, L.J., Farah, C.S., Accelerated wound healing phenotype in Interleukin 12/23 deficient mice. J. Inflamm., 8, 2011, 39, 10.1186/1476-9255-8-39.
51. Miao, F., et al. Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J. Biol. Chem. 282 (2007), 13854–13863, 10.1074/jbc.M609446200.
52. Mirza, R.E., Fang, M.M., Ennis, W.J., Koh, T.J., Blocking interleukin-1beta induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes. Diabetes 62 (2013), 2579–2587, 10.2337/db12-1450.
53. Mirza, R.E., Fang, M.M., Weinheimer-Haus, E.M., Ennis, W.J., Koh, T.J., Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes 63 (2014), 1103–1114.
54. Morris, D.L., Minireview emerging concepts in islet macrophage biology in type 2 diabetes. Mol. Endocrinol. 29 (2015), 946–962, 10.1210/me.2014-1393.
55. Mullican, S.E., et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev. 25 (2011), 2480–2488, 10.1101/gad.175950.111.
56. Nio, Y., et al. Monocyte chemoattractant protein-1 (MCP-1) deficiency enhances alternatively activated M2 macrophages and ameliorates insulin resistance and fatty liver in lipoatrophic diabetic A-ZIP transgenic mice. Diabetologia 55 (2012), 3350–3358, 10.1007/s00125-012-2710-2.
57. Noto, H., Goto, A., Tsujimoto, T., Osame, K., Noda, M., Latest insights into the risk of cancer in diabetes. J. Diabetes Invest. 4 (2013), 225–232, 10.1111/jdi.12068.
58. Odegaard, J.I., Chawla, A., Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat. Clin. Pract. Endocrinol. Metab. 4 (2008), 619–626, 10.1038/ncpendmet0976.
59. Odegaard, J.I., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 7 (2008), 496–507, 10.1016/j.cmet.2008.04.003.
60. Oh, D.Y., Morinaga, H., Talukdar, S., Bae, E.J., Olefsky, J.M., Increased macrophage migration into adipose tissue in obese mice. Diabetes 61 (2012), 346–354, 10.2337/db11-0860.
61. Olefsky, J.M., Glass, C.K., Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72 (2010), 219–246, 10.1146/annurev-physiol-021909-135846.
62. Petrillo, M., et al. Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer. PLoS One, 10, 2015, e0136654, 10.1371/journal.pone.0136654.
63. Reddy, M.A., et al. Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. Diabetes 63 (2014), 4249–4261, 10.2337/db14-0298.
64. Reuter, S., Gupta, S.C., Park, B., Goel, A., Aggarwal, B.B., Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 6 (2011), 93–108, 10.1007/s12263-011-0222-1.
65. Ruas, J.L., Poellinger, L., Pereira, T., Role of CBP in regulating HIF-1-mediated activation of transcription. J. Cell Sci. 118 (2005), 301–311, 10.1242/jcs.01617.
66. Satoh, N., et al. Unbalanced M1/M2 phenotype of peripheral blood monocytes in obese diabetic patients: effect of pioglitazone. Diabetes Care, 33, 2010, e7, 10.2337/dc09-1315.
67. Schubeler, D., Function and information content of DNA methylation. Nature 517 (2015), 321–326, 10.1038/nature14192.
68. Sterner, D.E., Berger, S.L., Acetylation of histones and transcription-related factors. Microbiolo. Mol. Biol. Rev.: MMBR 64 (2000), 435–459.
69. Suganami, T., Ogawa, Y., Adipose tissue macrophages: their role in adipose tissue remodeling. J. Leukoc. Biol. 88 (2010), 33–39, 10.1189/jlb.0210072.
70. Suganami, T., Nishida, J., Ogawa, Y., A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 2062–2068, 10.1161/01.ATV.0000183883.72263.13.
71. Sun, K., Kusminski, C.M., Scherer, P.E., Adipose tissue remodeling and obesity. J. Clin. Invest. 121 (2011), 2094–2101, 10.1172/JCI45887.
72. Tamura, Y., et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 2195–2201, 10.1161/ATVBAHA.108.168633.
73. Tateya, S., Kim, F., Tamori, Y., Recent advances in obesity-induced inflammation and insulin resistance. Front. Endocrinol., 4, 2013, 93, 10.3389/fendo.2013.00093.
74. Tausendschon, M., Dehne, N., Brune, B., Hypoxia causes epigenetic gene regulation in macrophages by attenuating Jumonji histone demethylase activity. Cytokine 53 (2011), 256–262, 10.1016/j.cyto.2010.11.002.
75. Van den Bossche, J., et al. Inhibiting epigenetic enzymes to improve atherogenic macrophage functions. Biochem. Biophys. Res. Commun. 455 (2014), 396–402, 10.1016/j.bbrc.2014.11.029.
76. Van den Bossche, J., Neele, A.E., Hoeksema, M.A., de Winther, M.P., Macrophage polarization: the epigenetic point of view. Curr. Opin. Lipidol. 25 (2014), 367–373, 10.1097/MOL.0000000000000109.
77. Wang, N., Liang, H., Zen, K., Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front. Immunol., 5, 2014, 614, 10.3389/fimmu.2014.00614.
78. Wu, D., et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332 (2011), 243–247, 10.1126/science.1201475.
79. Xiao, C., Giacca, A., Lewis, G.F., Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans. Diabetes 60 (2011), 918–924, 10.2337/db10-1433.
80. Yang, X., et al. Epigenetic regulation of macrophage polarization by DNA methyltransferase 3b. Mol. Endocrinol. 28 (2014), 565–574, 10.1210/me.2013-1293.
81. Ye, J., Gao, Z., Yin, J., He, Q., Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 293 (2007), E1118–1128, 10.1152/ajpendo.00435.2007.
82. Zeyda, M., Stulnig, T.M., Obesity, inflammation, and insulin resistance–a mini-review. Gerontology 55 (2009), 379–386, 10.1159/000212758.